Clinical Trial Update: Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating doxorubicin and carboplatin for recurrent ovarian cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Doxorubicin (doxorubicin)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Ovarian Cancer | Phase 1, Phase 2 | Status: WITHDRAWN